top of page
Telesphore-Pharma, BMSystems’ second therapeutic spin-off
Telesphore-Pharma (2020): Second BMSystems’ therapeutic spin-off, addresses Chronic Low-Grade Inflammatory Disorders (CLGID) with a First in class treatment for ME/CFS and a group of Post Covid-19 "long-haulers".
PRESS RELEASE: Paris November 30, 2020: Telesphore Pharma, the 2nd BMSystems' therapeutic spin-off is selected by the Biofit 2020 steering committee to pitch its First-in-class "Disease Centric Repositioning" Diagnosis and Treatment.
Why ME/CFS and why now?
The Covid-19 crisis is the unique opportunity to help people suffering from ME/CFS, provide the healthcare system with the tools for its diagnosis, monitoring and treatment and prevent as many "Post Covid-19 long-haulers" patients as possible from therapeutic wandering they’re already experiencing.
Telesphore Pharma aims to become the worldwide golden standard for the treatment and diagnosis of the disease.
ME/CFS Pharmacological treatment is a “disease-centric repositioning” of existing molecules addressing the causal mechanisms of the pathology. They have no toxicity nor side effects either individually or in combination. Technology patent ready to be filed.
bottom of page